The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer

Yan Ni Loh; Hedditch, Ellen L.; Baker, Laura A.; Jary, Eve; Ward, Robyn L.; Ford, Caroline E.
May 2013
BMC Cancer;2013, Vol. 13 Issue 1, p1
Academic Journal
Background: Acquired resistance to Tamoxifen remains a critical problem in breast cancer patient treatment, yet the underlying causes of resistance have not been fully elucidated. Abberations in the Wnt signalling pathway have been linked to many human cancers, including breast cancer, and appear to be associated with more metastatic and aggressive types of cancer. Here, our aim was to investigate if this key pathway was involved in acquired Tamoxifen resistance, and could be targeted therapeutically. Methods: An in vitro model of acquired Tamoxifen resistance (named TamR) was generated by growing the estrogen receptor alpha (ER) positive MCF7 breast cancer cell line in increasing concentrations of Tamoxifen (up to 5 uM). Alterations in the Wnt signalling pathway and epithelial to mesenchymal transition (EMT) in response to Tamoxifen and treatment with the Wnt inhibitor, IWP-2 were measured via quantitative RT-PCR (qPCR) and TOP/ FOP Wnt reporter assays. Resistance to Tamoxifen, and effects of IWP-2 treatment were determined by MTT proliferation assays. Results: TamR cells exhibited increased Wnt signalling as measured via the TOP/FOP Wnt luciferase reporter assays. Genes associated with both the β-catenin dependent (AXIN2, MYC, CSNK1A1) and independent arms (ROR2, JUN), as well as general Wnt secretion (PORCN) of the Wnt signalling pathway were upregulated in the TamR cells compared to the parental MCF7 cell line. Treatment of the TamR cell line with human recombinant Wnt3a (rWnt3a) further increased the resistance of both MCF7 and TamR cells to the anti-proliferative effects of Tamoxifen treatment. TamR cells demonstrated increased expression of EMT markers (VIM, TWIST1, SNAI2) and decreased CDH1, which may contribute to their resistance to Tamoxifen. Treatment with the Wnt inhibitor, IWP-2 inhibited cell proliferation and markers of EMT. Conclusions: These data support the role of the Wnt signalling pathway in acquired resistance to Tamoxifen. Further research into the mechanism by which activated Wnt signalling inhibits the effects of Tamoxifen should be undertaken. As a number of small molecules targeting the Wnt pathway are currently in pre-clinical development, combinatorial treatment with endocrine agents and Wnt pathway inhibitors may be a useful therapeutic option in the future for a subset of breast cancer patients.


Related Articles

  • MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Rao, X; Di Leva, G; Li, M; Fang, F; Devlin, C; Hartman-Frey, C; Burow, M E; Ivan, M; Croce, C M; Nephew, K P // Oncogene;3/3/2011, Vol. 30 Issue 9, p1082 

    Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies. However, after prolonged fulvestrant therapy, acquired resistance eventually occurs in...

  • Breast cancer: Reprogramming ER? Alderton, Gemma K. // Nature Reviews Cancer;Feb2012, Vol. 12 Issue 2, p79 

    The article discusses the importance of understanding the components of the transcription factor oestrogen receptor-α (ERα) to effectively target gene selection and improve the treatment of patients with breast cancer. It cites a study that determines and maps ERα chromatin binding via...

  • Characterization of molecular and structural determinants of selective estrogen receptor downregulators. Meiyun Fan; Emily Rickert; Lei Chen; Aftab, Syed; Nephew, Kenneth; Weatherman, Ross // Breast Cancer Research & Treatment;May2007, Vol. 103 Issue 1, p37 

    Antiestrogens used for breast cancer therapy can be categorized into two classes that differ in their effect on estrogen receptor (ER) alpha stability. The selective estrogen receptor modulators (SERMs) stabilize ER alpha and the selective estrogen receptor downregulators (SERDs) cause a...

  • Comparative Tolerability of First-Generation Selective Estrogen Receptor Modulators in Breast Cancer Treatment and Prevention. Curtis, M.G. // Drug Safety;Nov2001, Vol. 24 Issue 14, p1039 

    In general, the selective estrogen receptor modulators (SERMs) currently indicated for the treatment and prevention of breast cancer, i.e. tamoxifen and toremifene, are fairly well tolerated. However, tamoxifen has been shown to induce hepatocellular carcinomas in rats, but not in humans, and...

  • A CUE hints at tumor resistance. Thomas, Christoforos; Gustafsson, Jan-Ake // Nature Medicine;Jun2011, Vol. 17 Issue 6, p658 

    The article presents a study on the possible role of ubiquitin ligase 2 (CUEDC2) in endocrine resistance in breast tumors. A study shows that adjuvant treatment using estrogen receptor-inhibitor, tamoxefin do not responds to treatment of breast cancer due to endocrine-resistant tumors presented...

  • Progesterone receptor modulators in breast cancer. WIEHLE, Ronald D. // Turkish Journal of Biology;2014, Vol. 38 Issue 6, p772 

    Breast cancer has been treated successfully with selective estrogen receptor antagonists (SERMs) such as tamoxifen, receptor-depleting agents such as fulvestrant, and aromatase inhibitors such as anastrozole. Selective progesterone receptor modulators (SPRMs or PRMs) have not been studied as...

  • The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer. Jaouena, Gerard; Topa, Siden; Vessi�res, Anne; Leclercq, G.; McGlinchey, Michael J. // Current Medicinal Chemistry;Sep2004, Vol. 11 Issue 18, p2505 

    In the overall scheme of the future development of new drugs for the treatment of breast cancer, specially tamoxifen resistant tumours, we have explored the unprecedented use of organometallic SERMs. The initial idea is to enhance the efficacy of the current standard, i.e. tamoxifen, by...

  • Defining the Role of Raloxifene for the Prevention of Breast Cancer. Kalidas, Mamta; Hilsenbeck, Susan; Brown, Powel // JNCI: Journal of the National Cancer Institute;12/1/2004, Vol. 96 Issue 23, p1731 

    Compares the ability of tamoxifen and raloxifene to reduce the incidence of breast cancer in postmenopausal women at high risk of breast cancer. Implication of the study on the decision of the clinicians whether to use tamoxifen or raloxifene for the prevention of breast cancer; Determination of...

  • Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: Current State of Development. Gennari, Luigi; Merlotti, Daniela; Valleggi, Fabrizio; Martini, Giuseppe; Nuti, Ranuccio // Drugs & Aging;2007, Vol. 24 Issue 5, p361 

    Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as estrogen receptor agonists and antagonists. These drugs have been intensively studied over the past decade and have proven to be a highly...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics